血清CDH13甲基化对非肌层浸润性膀胱癌行TURBT治疗后进展的预测作用

目的 探索血清钙黏蛋白13(CDH13)甲基化对非肌层浸润性膀胱癌行经尿道膀胱肿瘤切除术(TURBT)治疗后进展的预测作用.方法 选取2010年1月至2012年1月在该院行TURBT治疗的非肌层浸润性膀胱癌患者98例,应用甲基化特异性PCR检测患者血清CDH13甲基化状态,并分析其与患者临床病理资料及术后进展情况的相关性.结果 52例(53.1％)患者血清中检测到CDH13甲基化,并且血清CDH13甲基化与肿瘤大小、分级及数目密切相关(P＜0.05).在随访过程中有20例(20.4％)患者出现肿瘤进展,Kaplan-Meier分析和log-rank检验发现存在血清CDH13甲基化的患者无进展生存率低于血清CDH13未甲基化的患者,差异有统计学意义(P=0.007).Cox回归分析显示,血清CDH13甲基化是非肌层浸润性膀胱癌行TURBT治疗后进展的独立危险因素.结论 血清CDH13甲基化可作为非肌层浸润性膀胱癌行TURBT治疗后进展的预测指标.

Predictive effect of serum CDH13 methylation for progression after TURBT in patients with non-muscle invasive bladder cancer

Objective To investigate the predictive effect of serum CDH13 methylation for the progression after TURBT in the patients with non-muscle invasive bladder cancer.Methods Ninety-eight patients with non-muscle invasive bladder cancer treated by TURBT in this hospital from January 2010 to January 2012 were selected.The methylation specific PCR was used to detect the methylation status of serum CDH13.Then its correlation with the clinicopathological data as well as postoperative progression situation was analyzed.Results Serum CDH13 methylation was detected in 52 cases (53.1％),moreover serum CDH13 methylation was closely correlated with tumor size,grade and number (P＜0.05).During follow-up,20 cases (20.4％) appeared the tumor progression.The Kaplan-Meier analysis and log-rank test found that the patients with serum CDH13 methylation had shorter progression-free survival rate than the patients without serum CDH13 methylation,and the difference was statistically significant (P=0.007).The Cox regression analysis showed that serum CDH13 methylation was an independent risk factor for the progression after TURBT in non-muscle invasive bladder cancer.Conclusion Serum CDH13 methylation can serve as a predictive indicator of the progression after TURBT in non-muscle invasive bladder cancer.